Synthesis and Pharmacological Properties of 1-(6-Aminohexylamino)-1-Phenylcyclohexyl Dihydrochloride (IEM-2062) as Compared with Memantine
- Authors: Gmiro V.E.1, Serdyuk S.E.1, Veselkina O.S.2
- 
							Affiliations: 
							- Institute of Experimental Medicine
- ZAO Vertex Pharmaceutical Company
 
- Issue: Vol 53, No 1 (2019)
- Pages: 29-34
- Section: Article
- URL: https://ogarev-online.ru/0091-150X/article/view/245596
- DOI: https://doi.org/10.1007/s11094-019-01950-z
- ID: 245596
Cite item
Abstract
1-(6-Aminohexylamino)-1-phenylcyclohexyl dihydrochloride (IEM-2062) had significantly greater antihypoxic, anticonvulsant, antidepressant, and analgesic activity than memantine and similar antiparkinsonism activity as memantine; it had low toxicity and was safer for use. IEM-2062 produced significant pharmacological effects in the dose range 0.3 – 3 mg/kg.
Keywords
About the authors
V. E. Gmiro
Institute of Experimental Medicine
							Author for correspondence.
							Email: gmiro2119@gmail.com
				                					                																			                												                	Russian Federation, 							12 Academician Pavlov Street, St. Petersburg, 197376						
S. E. Serdyuk
Institute of Experimental Medicine
														Email: gmiro2119@gmail.com
				                					                																			                												                	Russian Federation, 							12 Academician Pavlov Street, St. Petersburg, 197376						
O. S. Veselkina
ZAO Vertex Pharmaceutical Company
														Email: gmiro2119@gmail.com
				                					                																			                												                	Russian Federation, 							27A 24th Line, Vasilevskii Ostrov, St. Petersburg, 199106						
Supplementary files
 
				
			 
					 
						 
						 
						 
						 
				 
  
  
  
  
  Email this article
			Email this article  Open Access
		                                Open Access Access granted
						Access granted Subscription Access
		                                		                                        Subscription Access
		                                					